PCI Biotech - Rights Issue - NOK 360 million
PCI Biotech is a cancer focused biopharmaceutical company developing therapeutic products based on its proprietary photochemical internalization (PCI) technology. The PCI technology works by inducing triggered endosomal release and may be used to unlock the true therapeutic potential of a wide array of modalities. One bile duct cancer study is currently in clinical development. The company is also developing PCI as a CTL induction technology for therapeutic and prophylactic vaccination.
We thank PCI Biotech for the vote of confidence and congratulate on the transaction.
Latest news
Arctic Securities - Arctic top-ranked in Prospera 2025
Arctic Securities secured several leading positions in the Prospera Nordic High Yield Investor Survey 2025.
Arctic Securities - Arctic Securities Partners with Børsgruppen Aktie
Arctic Securities is pleased to partner with Børsgruppen Aktie at BI Norwegian Business School.
Arctic Securities - Welcome to Arctic, Jonas Abrahamsen!
Arctic is proud to welcome professional cyclist Jonas Abrahamsen as our newest ambassador.
Arctic Securities - Leadership Changes – Strengthening Arctic for the Future
We are pleased to announce leadership transitions at Arctic to support our long-term vision and continued success.
Arctic Securities - Arctic Securities er sertifisert rådgiver på Nasdaq First North Growth Market
Arctic Securities er godkjent som Certified Adviser (CA) på den alternative markedsplassen Nasdaq First North Growth Market i Sverige.
Arctic Securities - Arctic bøtelagt i Sverige – uenig i regelbrudd
Disiplinærnemnden ved Nasdaq Stockholm gir Arctic Securities en bot på 2 millioner SEK for ikke å ha informert børsen tidsnok om en endring i virksomheten.